AbCellera Biologics Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$16.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$7.21M.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$9.41M.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $5.74M, a 13.21% decline year-over-year.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $5.07M, a 22.23% increase year-over-year.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $3.46M, a 67.49% decline from fiscal 2024.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $10.63M.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$15.10M.
- AbCellera Biologics Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$2.09M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$16.62M 10-Q · filed 2026-08-05 | -$10.88M derived: sum of 3 quarters · filed 2026-08-05 | -$5.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$9.41M 10-Q · filed 2026-05-11 | -$3.66M derived: sum of 2 quarters · filed 2026-05-11 | $1.41M derived: sum of 3 quarters · filed 2026-05-11 | -$2.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.81M derived: sum of 2 quarters · filed 2026-02-24 | $6.87M derived: sum of 3 quarters · filed 2026-08-05 | $3.46M 10-K · filed 2026-02-24 |
| 2025-09-30 | $5.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.12M derived: sum of 2 quarters · filed 2026-08-05 | -$2.29M 10-Q · filed 2025-11-06 | $4.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$7.36M 10-Q · filed 2026-08-05 | -$739.00K derived: sum of 3 quarters · filed 2026-08-05 | $3.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.41M 10-Q · filed 2026-05-11 | $3.21M derived: sum of 2 quarters · filed 2026-05-11 | $7.36M derived: sum of 3 quarters · filed 2026-05-11 | $12.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $6.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.77M derived: sum of 2 quarters · filed 2026-02-24 | $15.51M derived: sum of 3 quarters · filed 2026-02-24 | $10.63M 10-K · filed 2026-02-24 |
| 2024-09-30 | $4.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.90M derived: sum of 2 quarters · filed 2025-11-06 | $4.02M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$130.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$4.88M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$15.10M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | -$2.09M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |